Zencore Biologics
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $225M
Overview
An independent Chinese CDMO providing end-to-end biologics development and manufacturing services, specializing in antibodies and ADCs for oncology and immunology.
OncologyImmunology
Technology Platform
End-to-end biologics CDMO platform with dedicated capabilities for mammalian cell culture, process/analytical development, and a specialized Antibody-Drug Conjugate (ADC) conjugation and manufacturing service.
Opportunities
High growth in ADC and complex biologic outsourcing, especially from Chinese biotechs, and potential to become a preferred Asian manufacturing partner for global companies seeking cost-effective, high-quality CDMO services.
Risk Factors
Intense competition from larger global CDMOs and other well-funded Chinese CDMOs, execution risk in scaling new large-scale facilities, and regulatory complexity in serving global markets from a China base.
Competitive Landscape
Competes with global CDMOs like Lonza and Samsung Biologics and Chinese peers such as WuXi Biologics and Pharmaron; differentiates through its dedicated ADC platform, in-house cell culture media production, and a pure-play service model without MAH conflicts.